AR074584A1 - Formulaciones farmaceuticas de conjugados camtotecina-polimero biocompatibles biodegradables - Google Patents

Formulaciones farmaceuticas de conjugados camtotecina-polimero biocompatibles biodegradables

Info

Publication number
AR074584A1
AR074584A1 ARP090104793A ARP090104793A AR074584A1 AR 074584 A1 AR074584 A1 AR 074584A1 AR P090104793 A ARP090104793 A AR P090104793A AR P090104793 A ARP090104793 A AR P090104793A AR 074584 A1 AR074584 A1 AR 074584A1
Authority
AR
Argentina
Prior art keywords
acid
tris
pharmaceutical formulation
formula
formulation according
Prior art date
Application number
ARP090104793A
Other languages
English (en)
Original Assignee
Mersana Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42243068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR074584(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mersana Therapeutics Inc filed Critical Mersana Therapeutics Inc
Publication of AR074584A1 publication Critical patent/AR074584A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe un sistema de liberación de un fármaco de fase dual de camptotecina/polímero que es estable tanto en estado líquido como liofilizado. El polímero contiene acetales y/o cetales. Reivindicación 1: Una formulación farmacéutica apropiada para administración endovenosa que comprende un compuesto de la fórmula (1) en donde uno de R1 es H o fórmula (2) y el otro es como en fórmula (3), uno de R2 es H o fórmula (2) y el otro es fórmula (2); CPT es camptotecina, n es 32-3320; m es 0-833; k es 1-216; en donde k, m y n se seleccionan de modo tal que aproximadamente 1% a aproximadamente 15% del compuesto en peso es camptotecina; un agente de estabilización, uno o varios tampones y un tensioactivo; en donde en peso molecular del compuesto va de aproximadamente 10 kD a aproximadamente 500 kD. Reivindicación 5: La formulación farmacéutica de acuerdo con la reivindicación 1, en donde el agente de estabilización está seleccionado del grupo que consiste en sorbitol, manitol, sacarosa, lactosa, glucosa, xilitol, maltosa, hidroxipropil-beta-ciclodextrina, lactitol, dextrosa, glicerina y maltitol. Reivindicación 14: La formulación farmacéutica de acuerdo con la reivindicación 1, en donde uno o varios tampones están seleccionados del grupo que consiste en citrato de sodio, ascorbato, succinato, lactato, ácido cítrico, ácido bórico, bórax, ácido clorhídrico, hidrógeno-fosfato disódico, ácido acético, ácido fórmico, glicina, bicarbonato, ácido tartárico, Tris-glicina, Tris-NaCl, Tris-ácido etilendiamintetraacético (EDTA), Tris-borato-EDTA, tris-acetato-EDTA ("TAE") tampón y solución salina tamponada con Tris, ácido 4-(2-hidroxietil)-1-piperazinetansulfónico ("HEPES"), ácido 3-(N-morfolino)propansulfónico ("MOPS"), ácido piperazin-1, 4-bis (2-etansulfónico) ("PIPES"), ácido 2-(N-morfolino)etansulfónico ("MES"), solución salina tamponada con fosfato ("PBS"), solución salina-citrato de sodio ("SSC"), solución salina-tris-EDTA ("STE") y tris-magnesio. Reivindicación 17: La formulación farmacéutica de acuerdo con la reivindicación 1, en donde el tensioactivo está seleccionado del grupo que consiste en Polysorbate 80, Polysorbate 20, Poloxamer 407, Solutol HS 15, Poloxamer 188, laurilsulfato sódico, etersulfatos, aceites sulfatados, cetrimide BP, cloruro de benzalconio, lecitina, cetromacrogel 1000 BPC y jabones de metales alcalinos de la fórmula RCOOX, donde R = grupo alquilo C10-20 y X = sodio, potasio o amonio. Reivindicación 23: La formulación farmacéutica de acuerdo con la reivindicación 1, en donde la formulación farmacéutica es una solución acuosa muy estable en almacenamiento. Reivindicación 24: La formulación farmacéutica de acuerdo con la reivindicación 1, en donde la formulación es una torta liofilizada apropiada para administración endovenosa después de reconstituir.
ARP090104793A 2008-12-10 2009-12-10 Formulaciones farmaceuticas de conjugados camtotecina-polimero biocompatibles biodegradables AR074584A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12138408P 2008-12-10 2008-12-10

Publications (1)

Publication Number Publication Date
AR074584A1 true AR074584A1 (es) 2011-01-26

Family

ID=42243068

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104793A AR074584A1 (es) 2008-12-10 2009-12-10 Formulaciones farmaceuticas de conjugados camtotecina-polimero biocompatibles biodegradables

Country Status (9)

Country Link
US (2) US8491880B2 (es)
KR (1) KR20110102420A (es)
CN (1) CN102307473A (es)
AR (1) AR074584A1 (es)
CL (1) CL2009002167A1 (es)
PA (1) PA8853201A1 (es)
PE (1) PE20100746A1 (es)
TW (1) TW201036639A (es)
WO (1) WO2010068759A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2553019A1 (en) * 2010-03-26 2013-02-06 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
US20180157397A1 (en) * 2016-04-08 2018-06-07 Maxx Media Group, LLC System and Method for Adding Three-Dimensional Images to an Intelligent Virtual Assistant that Appear to Project Forward of or Vertically Above an Electronic Display
EP3464400B1 (en) * 2016-06-03 2022-04-06 Novacyte Therapeutics Company.,LTD Polymer linkers and their uses
KR102617264B1 (ko) 2016-10-19 2023-12-29 인벤라 인코포레이티드 항체 구조물
EA201991204A1 (ru) 2016-12-22 2019-12-30 Университа Дельи Студи Манья Греча Катандзаро Моноклональное антитело против уникального сиалогликозилированного опухолеассоциированного эпитопа cd43
EP3641826B1 (en) 2017-06-22 2023-12-06 Mersana Therapeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
JP2021527047A (ja) 2018-06-05 2021-10-11 キングス・カレッジ・ロンドン 消化管系へのペイロード送達のための、ｂｔｎｌ３／８を標的とする構築物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4793986A (en) 1987-02-25 1988-12-27 Johnson Matthey, Inc. Macromolecular platinum antitumor compounds
JPH01190636A (ja) 1988-01-22 1989-07-31 Green Cross Corp:The 制癌作用物質複合体
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
EP0654973A4 (en) * 1992-07-21 1995-08-09 Gen Hospital Corp LYPHATIC TISSUE DRUG ADMINISTRATION SYSTEM.
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5612037A (en) * 1994-07-26 1997-03-18 Connaught Laboratories, Inc. Influenza virus subunit conjugates
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
EP0821001A4 (en) * 1995-03-31 2002-07-17 Drug Delivery System Inst Ltd AMIDITY DERIVATIVES AND OLIGONUCLEOTIDE DERIVATIVES
US5811510A (en) * 1995-04-14 1998-09-22 General Hospital Corporation Biodegradable polyacetal polymers and methods for their formation and use
CA2223433C (en) 1995-06-07 2003-11-18 Amgen Inc. Ob protein compositions and methods
SI0932399T1 (sl) 1996-03-12 2006-10-31 Pg Txl Co Lp Vodotopna paklitakselna predzdravila
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
AU783886B2 (en) 1999-06-18 2005-12-22 Innovata Plc Biologically active materials
IL131074A0 (en) 1999-07-23 2001-03-19 Polygene Ltd A biodegradable polycation composition for delivery of an anionic macromolecule
EP1206285A2 (en) 1999-08-09 2002-05-22 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6822086B1 (en) * 1999-08-09 2004-11-23 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
WO2002020663A2 (en) * 2000-09-06 2002-03-14 Ap Pharma, Inc. Degradable polyacetal polymers
US7838619B2 (en) * 2002-01-14 2010-11-23 The General Hospital Corporation Biodegradable polyketal polymers and methods for their formation and use
AU2003219796A1 (en) * 2002-02-20 2003-09-09 Beth Israel Deaconess Medical Center Conjugates comprising a biodegradable polymer and uses therefor
AU2003256613A1 (en) * 2002-07-19 2004-02-09 Amgen Inc. Protein conjugates with a water-soluble biocompatible, biogradable polymer
AU2003254023A1 (en) * 2002-07-19 2004-02-09 The General Hospital Corporation Oxime conjugates and methods for their formation and use
PT1534340E (pt) * 2002-09-06 2012-03-13 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
WO2004089311A2 (en) 2003-03-31 2004-10-21 Vectramed, Inc. Polymeric drug agents for the treatment of fibrotic disorders
ATE507845T1 (de) * 2003-09-05 2011-05-15 Gen Hospital Corp Polyacetal-arzneimittelkonjugate als freisetzungssystem
EP1547580A1 (en) 2003-12-23 2005-06-29 MediGene Oncology GmbH Loading of a camptothecin drug into colloidal nanoparticles
JP4840449B2 (ja) * 2007-01-31 2011-12-21 中央電気工業株式会社 炭素材料およびその製造方法
CA2706914A1 (en) * 2007-11-28 2009-06-11 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
US20120171118A1 (en) 2009-06-12 2012-07-05 The General Hospital Corporation Treatment of meningeal and neural diseases

Also Published As

Publication number Publication date
WO2010068759A1 (en) 2010-06-17
KR20110102420A (ko) 2011-09-16
CL2009002167A1 (es) 2010-10-15
PE20100746A1 (es) 2010-11-04
US20100179181A1 (en) 2010-07-15
TW201036639A (en) 2010-10-16
CN102307473A (zh) 2012-01-04
US8491880B2 (en) 2013-07-23
PA8853201A1 (es) 2010-07-27
US20140004074A1 (en) 2014-01-02

Similar Documents

Publication Publication Date Title
AR074584A1 (es) Formulaciones farmaceuticas de conjugados camtotecina-polimero biocompatibles biodegradables
KR101991367B1 (ko) 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
JP2019073563A5 (es)
AR080427A1 (es) Formulacion liquida para un conjugado de accion prolongada del g-csf
US11439652B2 (en) Ophthalmic aqueous composition
JP5616618B2 (ja) シリコーンハイドロゲルコンタクトレンズ用眼科組成物
BR112014013890A8 (pt) formulação em pó seco de derivado de azol para inalação
JP2013144671A (ja) 眼科用水性組成物
CN101400354A (zh) 水性组合物
JP2022008964A (ja) カラーコンタクトレンズ用眼科組成物
AR079561A1 (es) Forma de dosificacion farmaceutica oral que contiene un oligosacarido sintetico
JP7458159B2 (ja) 眼科組成物
JP5052028B2 (ja) アシタザノラスト含有組成物
EP3506947A1 (en) Pharmaceutical formulations of regadenoson
JP5419518B2 (ja) アズレン誘導体含有液剤
JP2006248960A (ja) 水性外用組成物
JP2018044013A (ja) 水性組成物
JP2007008928A (ja) アシタザノラスト含有水性組成物
IT202000025264A1 (it) Composizione iniettabile comprendente acido ialuronico e uso della detta composizione.
JP2019189607A (ja) 眼科組成物
JP2013144672A (ja) 眼科用水性組成物
CN106236704A (zh) 一种兼具仿生和靶向功能的莫西沙星滴眼液及其制备方法
JP6876017B2 (ja) オロパタジン含有水性組成物
JP7258478B2 (ja) イソプロピルメチルフェノールを含有する水性組成物
KR102288699B1 (ko) 수성 의약 조성물

Legal Events

Date Code Title Description
FB Suspension of granting procedure